Casticin, an Active Compound Isolated from Vitex Fructus, Ameliorates the Cigarette Smoke-induced Acute Lung Inflammatory Response in a Murine Model
Overview
Pharmacology
Affiliations
The aim of this study was to determine of the effect of casticin, as an anti-inflammatory agent, on an acute lung inflammation in vivo model established through exposure to cigarette smoke (CS). Casticin is a phytochemical from Vitex species such as Vitex rotundifolia and Vitex agnus-castus that was recently shown to exert an anti-inflammatory effect in vivo. To demonstrate the effects of casticin, C57BL/6 mice were whole-body exposed to mainstream CS or fresh air for two weeks and treated with 1, 2, and 10mg/kg casticin via an i.p. injection. Immune cell infiltrations and cytokine productions were assessed from bronchoalveolar lavage Fluid (BALF), and lung histological analysis was performed. Treatment with casticin was observed to significantly inhibit the numbers of total cells, neutrophils, macrophages, and lymphocytes and reduce the levels of proinflammatory cytokines and chemokines in the BALF. In addition, casticin significantly decreased the infiltration of peribronchial and perivascular inflammatory cells and the epithelium thickness. The results of this study indicate that casticin has significant effects on the lung inflammation induced by CS in a mouse model. According to these outcomes, casticin may have therapeutic potential in inflammatory lung diseases, such as chronic obstructive pulmonary disease (COPD).
Zhang Y, Wang L, Zeng J, Shen W Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40035820 DOI: 10.1007/s00210-025-03945-y.
Jia T, Xia Y, Yi M, Zhang X, Zheng Y, Che D Inflammopharmacology. 2025; .
PMID: 39821787 DOI: 10.1007/s10787-025-01639-8.
Traditional use, phytochemistry and pharmacology of Viticis Fructus.
Meng X, Wang H, Kuang Z, Wu Y, Su X, Wang J Heliyon. 2023; 9(9):e19144.
PMID: 37810114 PMC: 10558315. DOI: 10.1016/j.heliyon.2023.e19144.
Polyphenols, flavonoids and inflammasomes: the role of cigarette smoke in COPD.
Fu Y, Kang N, Yu Y, Mi Y, Guo J, Wu J Eur Respir Rev. 2022; 31(164).
PMID: 35705209 PMC: 9648508. DOI: 10.1183/16000617.0028-2022.
Li L, Zhang C, Zhu F, Zheng G, Liu Y, Liu K Front Pharmacol. 2022; 13:821941.
PMID: 35401201 PMC: 8988065. DOI: 10.3389/fphar.2022.821941.